CN101467975A - Pinaverium bromide sustained release tablets - Google Patents
Pinaverium bromide sustained release tablets Download PDFInfo
- Publication number
- CN101467975A CN101467975A CNA2007103084403A CN200710308440A CN101467975A CN 101467975 A CN101467975 A CN 101467975A CN A2007103084403 A CNA2007103084403 A CN A2007103084403A CN 200710308440 A CN200710308440 A CN 200710308440A CN 101467975 A CN101467975 A CN 101467975A
- Authority
- CN
- China
- Prior art keywords
- parts
- pinaverium
- sustained release
- release tablets
- eudragit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- IKGXLCMLVINENI-QOXGANSBSA-M [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC Chemical compound [Br-].COc1cc(Br)c(C[N+]2(CCOCC[C@@H]3CC[C@H]4C[C@@H]3C4(C)C)CCOCC2)cc1OC IKGXLCMLVINENI-QOXGANSBSA-M 0.000 title claims abstract description 29
- 229960002088 pinaverium bromide Drugs 0.000 title claims abstract description 29
- 239000007939 sustained release tablet Substances 0.000 title claims abstract description 15
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 10
- 208000002193 Pain Diseases 0.000 claims abstract description 8
- 230000036407 pain Effects 0.000 claims abstract description 8
- 238000002636 symptomatic treatment Methods 0.000 claims abstract description 8
- 230000004064 dysfunction Effects 0.000 claims abstract description 5
- 239000004014 plasticizer Substances 0.000 claims abstract description 5
- 208000008469 Peptic Ulcer Diseases 0.000 claims abstract description 4
- 208000003770 biliary dyskinesia Diseases 0.000 claims abstract description 4
- 210000003445 biliary tract Anatomy 0.000 claims abstract description 4
- 208000011906 peptic ulcer disease Diseases 0.000 claims abstract description 4
- 239000000945 filler Substances 0.000 claims abstract description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 22
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 claims description 16
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 14
- -1 pinaverium bromides Chemical class 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 12
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 12
- 229920001249 ethyl cellulose Polymers 0.000 claims description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
- 229960000361 pinaverium Drugs 0.000 claims description 12
- 239000001856 Ethyl cellulose Substances 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 229920003163 Eudragit® NE 30 D Polymers 0.000 claims description 4
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 4
- 201000007637 bowel dysfunction Diseases 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 claims description 2
- 229920003157 Eudragit® RL 30 D Polymers 0.000 claims description 2
- 229920003151 Eudragit® RL polymer Polymers 0.000 claims description 2
- 229920003161 Eudragit® RS 30 D Polymers 0.000 claims description 2
- 229920003134 Eudragit® polymer Polymers 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 claims description 2
- 239000001069 triethyl citrate Substances 0.000 claims description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 2
- 235000013769 triethyl citrate Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008991 intestinal motility Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the novel technical field of medicaments, and specifically relates to pinaverium bromide sustained release tablets for treating irritable bowel syndrome, pains of symptomatic treatment and intestinal dysfunction, intestinal motility disorder and upset, spastic colon, pains of symptomatic treatment and dysfunction of biliary tract, peptic ulcer and biliary dyskinesia. The pinaverium bromide sustained release tablets is composed of pinaverium bromide, filling agent, sustained release agent, plasticizer, and anti-sticking agent with the weight ratio of 150 : (10-500) : (10-300) : (0-100) : (0-100), and prepared as pulp by ethanol, wherein the weight of the anti-sticking agent is 1% of that of the ethanol. The pinaverium bromide sustained release tablets maintains substantially stable blood concentration and longer action time, and has the advantages of less side effect and convenient administration.
Description
Technical field
The invention belongs to the medicine new technical field, a kind of novel form that relates to pinaverium bromide, be used for the treatment of irritable bowel syndrome, symptomatic treatment pain, the enterokinesia relevant with bowel dysfunction reaches discomfort unusually, spastic colon, the pain that symptomatic treatment is relevant with the biliary tract dysfunction, peptic ulcer, pharmaceutical preparation of biliary dyskinesia and preparation method thereof, specifically a kind of pinaverium bromide sustained release tablets.
Background technology
Irritable bowel syndrome (IBS) is a very general gastrointestinal function unrest, accounts for the crowd's of growing up 14%～22%.With stomachache, abdominal distention, bowel habit sexually revise with character be cardinal symptom unusually, be one and the chronic bowel dysfunction disease that does not have organic change.Show that by people's clinical research in recent years the therapeutic effect of pinaverium bromide is much better than similar other drug, and safety, side effect is rare, and the patient has good tolerability to this medicine.There are some researches show that also pinaverium bromide after using 7 days, can obviously reduce the frequency and the degree of stomachache to the best results of treatment stomachache, total effective rate is 93%.
Pinaverium bromide is a gastrointestinal selectivity calcium channel blocker, flows into the intestinal wall smooth muscle cell by the blocking-up calcium ion, and the activation of " last common pathway " calcium channel of active all mechanism of gastrointestinal tract is regulated in blocking-up, and prevents that the muscle excess shrinkage from reaching spasmolysis.Experimental results show that this medicine does not have the anticholinergic effect, do not have the side effect of cardiovascular system, old people's cardiovascular patient is had no adverse effects, but glaucoma and prostate hyperplasia person also safety clothes use.
Summary of the invention
The object of the invention is to provide a kind of pinaverium bromide sustained release tablets, and it is used for the treatment of irritable bowel syndrome, and symptomatic treatment pain, the enterokinesia relevant with bowel dysfunction reaches discomfort unusually, spastic colon, the pain that symptomatic treatment is relevant with the biliary tract dysfunction, peptic ulcer, biliary dyskinesia.This drug slow discharges to be kept comparatively stable blood concentration and longer action time, has the toxic and side effects minimizing and takes advantages such as convenient.
This invention is that every contained pinaverium bromide is 50mg～500mg, preferred 100mg～200mg.
Weight of the present invention is formed and is comprised:
150 parts of pinaverium bromides
10～150 parts of binding agents
10～300 parts of slow-release materials
0～100 part of plasticizer
0～100 part of antiplastering aid
10～500 parts of filleies
Above-mentioned slow-release material be meant one of ethyl cellulose, stearic acid, cellulose acetate, Eudragit (acrylic resin) RS100, Eudragit RL100, Surelease (Aquacoat), Eudragit RS 30D, Eudragit RL 30D, Eudragit NE 30D or they optional two or more.
Above-mentioned plasticizer is meant polyethylene glycol 6000, diethyl phthalate or triethyl citrate.
Above-mentioned antiplastering aid is meant Pulvis Talci, magnesium stearate.
Above-mentioned filler is one or more mixing wherein such as microcrystalline Cellulose, lactose, starch, magnesium stearate, Pulvis Talci, hydroxypropyl emthylcellulose series, Polyethylene Glycol series, dextrin, mannitol, methylcellulose, ethyl cellulose.
Wherein, the preferred weight composition of the present invention comprises:
150 parts of pinaverium bromides
20～200 parts of ethyl celluloses
1～15 part of diethyl phthalate
20～200 parts of lactose
5～50 parts of Pulvis Talci; Perhaps
150 parts of pinaverium bromides
25～250 parts of stearic acid
20～150 parts of lactose
20～150 parts of microcrystalline Cellulose
5～50 parts of Pulvis Talci; Perhaps
150 parts of pinaverium bromides
20～262 parts of EudragitRS100
10～100 parts of polyethylene glycol 6000s
30～300 parts of microcrystalline Cellulose
3～100 parts of Pulvis Talci; Perhaps
150 parts of pinaverium bromides
100 20～200 parts of Eudragit RL
2～80 parts of polyethylene glycol 6000s
20～200 parts in dextrin
5～50 parts of Pulvis Talci; Perhaps
150 parts of pinaverium bromides
30～300 parts of Eudragit NE 30D
30～200 parts of starch
30～200 parts in dextrin
10～100 parts of Pulvis Talci
Pinaverium bromide sustained release tablets of the present invention can be kept comparatively stable blood concentration and longer action time, have toxic and side effects little, take convenient advantage.Domestic do not have this dosage form to go on the market, and therefore, develops this product and will obtain social benefit and economic benefit widely.
The specific embodiment is as follows, but does not limit the present invention in any way.
Embodiment:
Embodiment 1:
Pinaverium bromide 150g
Ethyl cellulose 50g
Diethyl phthalate 10g
Lactose 150g
Pulvis Talci 10g
95% ethanol is an amount of
Preparation technology: with 95% dissolve with ethanol ethyl cellulose and diethyl phthalate, add pinaverium bromide while stirring, make dissolving fully, fling to ethanol, add the lactose and the Pulvis Talci of recipe quantity, mix homogeneously, tabletting, promptly.
Embodiment 2:
Pinaverium bromide 150g
Ethyl cellulose 15g
Stearic acid 25g
Diethyl phthalate 2g
Pulvis Talci 10g
Microcrystalline Cellulose 200g
95% ethanol is an amount of
Preparation technology: with 95% dissolve with ethanol ethyl cellulose, diethyl phthalate and stearic acid, add pinaverium bromide while stirring, make dissolving fully, fling to ethanol, add the microcrystalline Cellulose and the Pulvis Talci of recipe quantity, mix homogeneously, tabletting, promptly.
Prescription C:
Pinaverium bromide 150g
Ethyl cellulose 20g
Eudragi?tRS100 25g
Polyethylene glycol 6000 10g
Pulvis Talci 15g
Microcrystalline Cellulose 250g
95% ethanol is an amount of
Preparation technology: with 95% dissolve with ethanol ethyl cellulose, EudragitRS100 and polyethylene glycol 6000, add pinaverium bromide while stirring, make dissolving fully, fling to ethanol, add the microcrystalline Cellulose and the Pulvis Talci of recipe quantity, mix homogeneously, tabletting, promptly.
Embodiment 3:
Pinaverium bromide 150g
EudragitRL?100 35g
EudragitRS?100 55g
Polyethylene glycol 6000 4.5g
Pulvis Talci 10g
Microcrystalline Cellulose 150g
Lactose 50g
95% ethanol is an amount of
Preparation technology: with 95% dissolve with ethanol EudragitRL 100, EudragitRS100 and polyethylene glycol 6000, add pinaverium bromide while stirring, make dissolving fully, fling to ethanol, add microcrystalline Cellulose, lactose and the Pulvis Talci of recipe quantity, mix homogeneously, tabletting, promptly.
Claims (7)
1. pinaverium bromide sustained release tablets is characterized in that its weight is formed to comprise:
150 parts of pinaverium bromides
10～150 parts of binding agents
10～300 parts of slow-release materials
0～100 part of plasticizer
0～100 part of antiplastering aid
10～500 parts of filleies
Described slow-release material be meant one of ethyl cellulose, stearic acid, cellulose acetate, Eudragit (acrylic resin) RS100, Eudragit RL100, Surelease (Aquacoat), Eudragit RS 30D, Eudragit RL 30D, Eudragit NE 30D or they optional two or more.
Above-mentioned plasticizer is meant polyethylene glycol 6000, diethyl phthalate or triethyl citrate.
Above-mentioned antiplastering aid is meant Pulvis Talci, magnesium stearate.
Above-mentioned filler is one or more mixing wherein such as microcrystalline Cellulose, lactose, starch, magnesium stearate, Pulvis Talci, hydroxypropyl emthylcellulose series, Polyethylene Glycol series, dextrin, mannitol, methylcellulose, ethyl cellulose.
2. according to the described pinaverium bromide sustained release tablets of claim 1, it is characterized in that its weight composition comprises:
150 parts of pinaverium bromides
20～200 parts of ethyl celluloses
1～15 part of diethyl phthalate
5～50 parts of Pulvis Talci
20～200 parts of lactose
3. according to the described pinaverium bromide sustained release tablets of claim 1, it is characterized in that its weight composition comprises:
150 parts of pinaverium bromides
25～250 parts of stearic acid
5～50 parts of Pulvis Talci
20～150 parts of lactose
20～150 parts of microcrystalline Cellulose
4. according to the described pinaverium bromide sustained release tablets of claim 1, it is characterized in that its weight composition comprises:
150 parts of pinaverium bromides
20～262 parts of EudragitRS100
10～100 parts of polyethylene glycol 6000s
3～100 parts of Pulvis Talci
30～300 parts of microcrystalline Cellulose
5. according to the described pinaverium bromide sustained release tablets of claim 1, it is characterized in that its weight composition comprises:
150 parts of pinaverium bromides
100 20～200 parts of Eudragit RL
2～80 parts of polyethylene glycol 6000s
5～50 parts of Pulvis Talci
20～200 parts in dextrin
6. according to the described pinaverium bromide sustained release tablets of claim 1, it is characterized in that its weight composition comprises:
150 parts of pinaverium bromides
30～300 parts of Eudragit NE 30D
10～100 parts of Pulvis Talci
30～200 parts in dextrin
7. want-1 described pinaverium bromide sustained release tablets according to right, it is characterized in that this slow releasing tablet is to be used for the treatment of irritable bowel syndrome, symptomatic treatment pain, the enterokinesia relevant with bowel dysfunction reaches discomfort unusually, spastic colon, the pain that symptomatic treatment is relevant with the biliary tract dysfunction, peptic ulcer, biliary dyskinesia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007103084403A CN101467975A (en) | 2007-12-29 | 2007-12-29 | Pinaverium bromide sustained release tablets |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007103084403A CN101467975A (en) | 2007-12-29 | 2007-12-29 | Pinaverium bromide sustained release tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101467975A true CN101467975A (en) | 2009-07-01 |
Family
ID=40825939
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007103084403A Pending CN101467975A (en) | 2007-12-29 | 2007-12-29 | Pinaverium bromide sustained release tablets |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101467975A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116459222A (en) * | 2023-04-20 | 2023-07-21 | 山东中医药大学附属医院 | A kind of pinaverium bromide composition, preparation and application thereof |
| CN117717531A (en) * | 2023-11-21 | 2024-03-19 | 广州仁恒医药科技股份有限公司 | Pivelum bromide tablet and preparation method thereof |
-
2007
- 2007-12-29 CN CNA2007103084403A patent/CN101467975A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116459222A (en) * | 2023-04-20 | 2023-07-21 | 山东中医药大学附属医院 | A kind of pinaverium bromide composition, preparation and application thereof |
| CN117717531A (en) * | 2023-11-21 | 2024-03-19 | 广州仁恒医药科技股份有限公司 | Pivelum bromide tablet and preparation method thereof |
| CN117717531B (en) * | 2023-11-21 | 2025-04-11 | 广州仁恒医药科技股份有限公司 | A kind of pinaverium bromide tablets and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| RU2011123876A (en) | ANTISENSE COMPOSITIONS AND METHODS FOR PRODUCING AND USING THEM | |
| BR112012024019B1 (en) | CONTROLLED RELEASE DOSAGE FORM FOR ORAL ADMINISTRATION | |
| HRP20090679T1 (en) | USE OF OXYCODONE FOR THE TREATMENT OF ORGANIC PAIN | |
| JP2018520112A (en) | Controlled sustained release pregabalin | |
| CN108159011A (en) | A kind of Pregabalin stomach retention sustained-release piece of biphasic controlled release and preparation method thereof | |
| KR102194174B1 (en) | Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome | |
| MX2015004296A (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof. | |
| CN101467975A (en) | Pinaverium bromide sustained release tablets | |
| RU2018131573A (en) | METHOD FOR TREATING CANCER PATIENTS WITH SEVERE RENAL FAILURE | |
| ES2899885T3 (en) | New differential release pharmaceutical composition containing three active ingredients | |
| CN106214653A (en) | A kind of FCE-26743A slow releasing tablet and preparation method thereof | |
| CN101849942B (en) | Pharmaceutical composition for treating hypertension | |
| KR20140118412A (en) | Slow release pharmaceutical composition having Eperisone as active ingredient | |
| CN102397278A (en) | Antihypertensive medicine composition | |
| CN103099776A (en) | Koumine sustained-release preparation and preparation method thereof | |
| CN102485228A (en) | Pharmaceutical composition and purpose thereof | |
| CN106420654A (en) | Metformin hydrochloride enteric-coated tablet medicine composition with reduced untoward effect | |
| WO2016203358A1 (en) | Extended release capecitabine capsules | |
| CN100391459C (en) | Doxazosin Mesylate Sustained Release Preparation | |
| CN104721162A (en) | Prednisone oral pulsatile tablet and preparation method thereof | |
| CN104840480B (en) | Metformin/folic acid/vitamin B12New application of pharmaceutical composition | |
| CN101756991B (en) | Sustained-release pills of alfuzosin hydrochloride | |
| CN105663072B (en) | A kind of dianhydrogalactitol thin membrane coated tablet and preparation method thereof | |
| CN103040798A (en) | Bezafibrate slow release pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090701 |